Evidence map›Paper›PMID 25129854›Full record

ArticleEuropean urology2015

Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.

Xiaoyi Huang, Tiezheng Yuan, Meihua Liang, Meijun Du, Shu Xia, Rachel Dittmar, Dian Wang, William See, Brian A Costello, Fernando Quevedo and 11 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04662996 (Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs), which is not on this map. Cited by 386 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
386citing papers in PubMed, 4 pooled it
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04662996 nacompletednot on this mapstarted 2021, after this paper: background citation

Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs

TypeinterventionalSponsorUniversity Hospital, ToursRan2021 to 2023Enrolled33ConditionsProstate Cancer, Resistance, Disease, MicroRNAsArmsBlood sample
3 · Its place in the literature

Who cites it

386 citing papers in PubMed, 4 syntheses or guidelines pooled it, 696 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

326 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Xiaoyi HuangDepartment of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA; Biotherapy Center, Third Affiliated Hospital of Harbin Medical University, Harbin, China.
Tiezheng YuanDepartment of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Meihua LiangDepartment of Endocrinology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Meijun DuDepartment of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Shu XiaDepartment of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA; Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rachel DittmarDepartment of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Dian WangDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
William SeeDepartment of Urology, Medical College of Wisconsin, Milwaukee, WI, USA.
Brian A CostelloDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Fernando QuevedoDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Winston TanDepartment of Oncology, Mayo Clinic, Jacksonville, FL, USA.
Debashis NandyDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Graham H BevanUniversity of Rochester Medical Center, Rochester, NY, USA.
Sherri LongenbachDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Zhifu SunDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Yan LuDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Tao WangDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.
Stephen N ThibodeauDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Lisa BoardmanDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Manish KohliDepartment of Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: kohli.manish@mayo.edu.
Liang WangDepartment of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: liwang@mcw.edu.
Medical College of Wisconsin · USMayo Clinic in Arizona · USHarbin Medical University · CNMayo Clinic · USTongji Hospital · CNUniversity of Rochester Medical Center · USWinnMed · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Genetic determinants of gene expression phenotypes in aggressive prostate cancerR01CA157881 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI WANG, LIANG · 2011 to 2016
$2.9M
NCATS NIH HHS UL1 TR000135NCI NIH HHS R01 CA157881NCI NIH HHS R01CA157881
6 · The paper itself

Abstract

backgroundExtracellular microRNAs (miRNAs) embedded in circulating exosomes may serves as prognostic biomarkers in cancer.

objectiveTo identify and evaluate plasma exosomal miRNAs for prognosis in castration-resistant prostate cancer (CRPC). DESIGN, SETTING, AND

participantsRNA sequencing was performed to identify candidate exosomal miRNAs associated with overall survival in a screening cohort of 23 CRPC patients. Candidate miRNAs were further evaluated for prognosis using quantitative real-time polymerase chain reaction in a follow-up cohort of 100 CRPC patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox regression and Kaplan-Meier survival analyses were used to evaluate survival association using candidate miRNAs along with clinical prognostic factors. RESULTS AND LIMITATIONS: RNA sequencing in screening cohort generated approximately 6.80 million mappable reads per patient. Of those with normalized read counts ≥ 5, 43% were mapped to miRNAs for a total of 375 known and 57 novel miRNAs. Cox regression analysis identified an association of miR-1290, -1246, and -375 with overall survival (false discover rate < 0.05). Of those, higher levels of miR-1290 and -375 were significantly associated with poor overall survival (p < 0.004) in the follow-up cohort. Incorporation of miR-1290/-375 into putative clinical prognostic factors-based models in CRPC stage significantly improved predictive performance with a time-dependent area under the curve increase from 0.66 to 0.73 (p = 6.57 × 10(-6)).

conclusionsPlasma exosomal miR-1290 and miR-375 are promising prognostic biomarkers for CRPC patients. Prospective validation is needed for further evaluation of these candidate miRNAs. PATIENT SUMMARY: In this study, we evaluated whether small RNAs circulating in blood could be used to predict clinical outcomes in late-stage prostate cancer patients. We identified two blood-based small RNAs whose levels showed significant association with survival. Our results warrant further investigation because the noninvasive blood-based test has great potential in the management of late-stage prostate cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorExosomesHumansKaplan-Meier EstimateMaleMicroRNAsMiddle AgedPrognosisProportional Hazards ModelsProstatic Neoplasms, Castration-ResistantSurvival RateBiomarkers, TumorMicroRNAsMIRN1290 microRNA, humanMIRN375 microRNA, humanBiomarkerExosomeExtracellular RNAmicroRNAPrognosisProstate cancerRNA sequencingSurvival

Identifiers

PMID25129854
PMCPMC4252606
OpenAlexW1995405710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.